// App-Quantinova.ai

OP0269 (2021) : A COMBINED CLINICAL AND BIOMARKER ALGORITHM TO PREDICT FVC DECLINE IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM AN INTERNATIONAL MULTICENTRE OBSERVATIONAL COHORT

Researchers

Presenter

  • M. Hutchinson

Principal Investigators

  • G. Abignano

  • J. Blagojevic

  • S. L. Bosello

  • Y. Allanore

  • C. Denton

  • O. Distler

  • P. Emery

  • M. Matucci-Cerinic

  • F. Del Galdo

Medical Centers

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom

  • University of Florence, Florence, Italy

  • Universita la Cattolica, Rheumatology, florence, Italy

  • Rheumatology, Cahors, France

  • University College London, Gastroenterology, London, United Kingdom

  • UniversitÄtsSpital Zürich, Rheumatology, Zürich, Switzerland

Locations

  • United Kingdom

  • Italy

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • Procollagen III N-Terminal Propeptide

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • ALPINE PHARMA PVT.LTD

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved